





## **FAX Completed Form To** 1.833.404.2392

**Prescriber Help Desk** 1.833.587.2012

Online

covermymeds.com/main/

## **Request for Prior Authorization** APREMILAST (OTEZLA®)

(PLEASE PRINT - ACCURACY IS IMPORTANT) prior-authorization-forms/ IA Medicaid Member ID # Patient name DOB Patient address Provider NPI Phone Prescriber name Prescriber address Fax Address Phone Pharmacy name Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. Pharmacy NPI Pharmacy fax NDC

Prior authorization is required for apremilast (Otezla®). Payment will be considered under the following conditions:

- 1. Request adheres to all FDA approved labeling for indication, including age, dosing and contraindications; and
- 2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints); with documentation of a trial and inadequate response to therapy with the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); or
- 3. Patient has a diagnosis of plaque psoriasis; with documentation of a trial and inadequate response to phototherapy, systemic retinoids, methotrexate, or cyclosporine; or
- 4) Patient has a diagnosis of Behçet disease; with
  - a. Documentation of active oral ulcers associated with Behçet disease; and
  - b. Documentation of a previous trial and inadequate response, at a therapeutic dose, to colchicine.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically

contraindicated.	<b>,</b>				<b>,</b>
Preferred	_				
Otezla	Strength	Dosage Instructions	Quantity	Days Supply	
Diagnosia			<u> </u>		
Diagnosis.					
☐ Psoriatic Art	thritis				
Treatment failure	with oral methotre	kate (leflunomide or sulfasalazine	e if methotrexate is cor	ntraindicated):	
Drug Name & Do	ose:	Tria	al dates:		
Reason for failure	e:				
☐ Plaque Psor					
		systemic retinoids, methotrexate	e. or cyclosporine:		
Drug Name & Dose: Trial dates:					
Behçet Dise		associated with Behçet disease'	? □ Yes □ No		
•		ug Name & Dose:	<del></del>	al datas:	
				al dates:	
Reason for failure	<del>с</del>				_
Possible drug into	eractions/conflicting	drug therapies:			
		mentation as necessary.			
		rescriber listed above.)	Date of s	submission	

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.